

Tackling Low-Value Clinical Care: Background

Task Force on Low-Value Care

September 2018

Outline

1. Background on Low-Value Care


2. Why a Task Force

3. Top Five List and News

4. Levers

5. Resources

A Taxonomy of Waste



Why Clinical Waste?

2012 Analysis:
34% of
Spend Wasted

2017 Physician Survey:
21% of
Care Unneeded

SPECIAL COMMUNICATION

ONLINE FIRST

Eliminating Waste in US Health Care

Donald M. Berwick, MD, MPP
Andrew D. Hackbart, MPH

The need is urgent to bring US health care cost both public and private payers. Common cuts, such as reductions in payment rates, are likely to be harmful. A less harmful strategy would be to reduce the waste that is inherent in the current system. The opportunity is immense. In just one year, the potential savings from a more coordinated, comprehensive approach to waste are far greater than the current total of waste. The potential for waste reduction is enormous. The literature in this area identifies many potential sources of waste and provides a broad range of estimates of the magnitude of excess spending.¹⁻⁶ Six categories, at least,

Reducing Waste in Health Care Spending

Here is a better idea: cut waste. That is, a basic strategy for survival in most industries today, ie, to keep processes, products, and services that actually help customers and systematically remove the elements of work that do not.

The opportunity for waste reduction in health care is enormous. The literature in this area identifies many potential sources of waste and provides a broad range of estimates of the magnitude of excess spending.¹⁻⁶ Six categories, at least,

OPEN ACCESS

Check for updates

Check for updates

OPEN ACCESS

Citation: Lyu H, Xu T, Brotnan D, Mayer-Blackwell B, Cooper M, Daniel M, et al. (2017) Overtreatment in the United States. *PLoS ONE* 12(9): e0181970. <https://doi.org/10.1371/journal.pone.0181970>

Editor: Irenka K. Mose, University of Miami, UNITED STATES

Received: March 24, 2017

Accepted: July 10, 2017

Published: September 6, 2017

Copyright: © 2017 Lyu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All of our data is owned by a third party. The authors had no special access privileges to the data. The third party is QuantifiMD and their contact information is info@quantifimd.com or +1.800.724.1482.

Funding: This work was supported by the Richard Foundation; no grant number available (RM). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Check for updates

OPEN ACCESS

Citation: Lyu H, Xu T, Brotnan D, Mayer-Blackwell B, Cooper M, Daniel M, et al. (2017) Overtreatment in the United States. *PLoS ONE* 12(9): e0181970. <https://doi.org/10.1371/journal.pone.0181970>

Editor: Irenka K. Mose, University of Miami, UNITED STATES

Received: March 24, 2017

Accepted: July 10, 2017

Published: September 6, 2017

Copyright: © 2017 Lyu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All of our data is owned by a third party. The authors had no special access privileges to the data. The third party is QuantifiMD and their contact information is info@quantifimd.com or +1.800.724.1482.

Funding: This work was supported by the Richard Foundation; no grant number available (RM). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

PLOS ONE

RESEARCH ARTICLE

Overtreatment in the United States

Heather Lyu^{1*}, Tim Xu², Daniel Brotnan³, Brandon Mayer-Blackwell⁴, Michol Cooper⁵, Michael Daniel⁶, Elizabeth C. Wink⁷, Vikas Sami⁸, Shannon Browne⁹, Martin A. Makary^{1,4}

1 Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, **2** United States of America, **3** Department of Surgery and the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, **4** Massachusetts, United States of America, **5** Department of the Department of Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, America

* lyu@partners.org

Check for updates

Abstract

Background

Overtreatment is a cause of preventable overall medical care that is unnecessary, including overutilization of clinical perspectives on the prevalence, causes, and implications.

Methods

2,106 physicians from an online national Association (AMA) masterfile par extent of overutilization, as well as ca outcome measures included: percent, called reasons of overtreatment, patient profit and overtreatment.

Findings

The response rate was 70.1%. Physicians reported overall medical care was unnecessary, including tests, and 11.1% of procedures. The most common reasons for unnecessary care were: patient pressure/request (50.8%), unnecessary tests (38.2%), and unnecessary procedures (38.2%). Potential solutions identified were training (55.2%), easy access to outside health records (52.0%), and 51.5%. Most respondents (70.8%) believed that physicians are necessary procedures when they profit from them. Most respondents believing free-for-service physician compensation would reduce health care utilization and patient profit and overtreatment.

Conclusion

From the physician perspective, overtreatment is common. Efforts to address the problem should consider the causes and solutions offered by physicians.

OPEN ACCESS


Check for updates

Why Clinical Waste?

- **Order of magnitude: \$200 – 400 Billion annual spending on wasteful care**
- Both a financial imperative
 - Spending on low-value clinical care reduces headroom for high-value care
- And a moral imperative
 - Patient harm



Why Low-Value Care?



...But Minimal Progress from Information-Only...

Prevalence and Trends for Six Commonly Overused Services (2010-2013)





Figure derived from: Rosenberg A, Agiro A, Gottlieb M, et al. Early Trends Among Seven Recommendations from the Choosing Wisely Campaign. *JAMA Intern Med.* 2015;175(12):1913-1920.

(At least) we know we can do better.

Distribution of Provider Organizations by Count of Low-Value Services Delivered per Medicare Beneficiary Per Year



Building a Top Five List

Key Criteria

Unit Price

Volume

**Aggregate
Cost**

Harm

**Political
Sensitivity**

**High Waste
Index**

5 Commonly Overused Services Ready for Purchaser Action



1. Diagnostic Testing and Imaging Prior to Surgery



2. Vitamin D Screening



3. PSA Screening in Men 75+



4. Imaging in First 6 Weeks of Low Back Pain



5. Branded Drugs When Identical Generics Are Available

1. Unindicated Diagnostic Testing and Imaging in Low-Risk Patients Prior to Low-Risk Surgery



WHAT

Low-risk patients undergoing low-risk surgery do not need many commonly provided blood tests, imaging services, and more.

WHY

Unneeded tests and imaging services:

- Rarely change patient management
- Identify clinically insignificant abnormalities
- Delay needed care (opportunity cost too)

BURDEN

Nationwide in 2014:

- About **19 million** unneeded pre-surgery tests/images performed
- About **\$9.5 billion** in spending resulted

2. Vitamin D Screening



WHAT

Population-based screening for 25-OH-Vitamin D deficiency should be avoided.

WHY

Vitamin D deficiency is rare. If deficiency suspected, patients should simply be advised to take an over-the-counter supplement and increase sun exposure.

BURDEN

Nationwide in 2014:

- About **6.3 million** unneeded screening tests performed
- About **\$800 million** in spending resulted

Background: Top Five

Top Five in the News



- “The Man Who Sold America on Vitamin D – And Profited In the Process”

– Liz Szabo



The New York Times

2. Vitamin D Screening



3. Prostate-specific antigen (PSA) screening in men 75 and older



WHAT

In men 75 and older, screening for prostate cancer through the PSA blood test should almost never be performed.

WHY

- Over-diagnosis associated with serious harm
- Harms of screening in men 75+ unambiguously outweigh benefit

BURDEN

Nationwide in 2014:

- At least **1 million** unneeded screenings in men 75+ performed
- Tests alone resulted in at least **\$44 million** in spending

4. Imaging for acute low-back pain for first six weeks after onset, unless clinical warning signs are present



WHAT

X-rays, computed tomography (CT), and magnetic resonance imaging (MRI) should be avoided during first six weeks of low-back pain, unless a specific clinical warning sign is present.

WHY

- Rarely changes patient management
- X-rays and CT expose patients to unneeded radiation
- Detects clinically insignificant abnormalities

BURDEN

Nationwide in 2014:

- About **1.6 million** avoidable imaging services performed
- About **\$500 million** in spending resulted

5. Use of more expensive branded drugs when generics with identical active ingredients are available



WHAT

Branded medications should not be prescribed when less expensive, chemically identical generics are available. (This is distinct from therapeutic substitution, when non-equivalent medications are substituted for one another.)

WHY


Prescribing of more expensive, chemically identical medications buys no extra health per dollar.

BURDEN

Purchasers would have saved \$14.7 billion in 2016 had 100% of prescriptions with generics available been dispensed as generics

Top Five in the “News”

Figure 1: Effects of Moving to Full Generic Substitution in Part D.¹²



- Part D spent almost \$9 billion in brand name drugs when equivalent generics were available, an opportunity to save \$2.8 billion.



U.S. Department of Health and Human Services
Office of the Assistant Secretary for Planning and Evaluation

5. Use of more expensive branded drugs when generics with identical active ingredients are available



Top Five in the News

“The few. The effective. The cheapest. The waste-free formulary.”



- PGBH is developing a “waste-free” formulary for purchasers to increase use of low-cost alternatives.

5. Use of more expensive branded drugs when generics with identical active ingredients are available



Top Five Relevance

MEDPAC



- June MedPAC report
- Our Top Five Featured:
 - Imaging for nonspecific low back pain
 - PSA screening at age ≥ 75
 - Preoperative testing before low-risk surgery
 - Vitamin D testing in absence of hypercalcemia or decreased kidney function

Top Five Relevance

NHS wields the axe on 17 'unnecessary procedures'

Varicose vein surgery and tonsil removal feature on list of routine operations to be axed



- NHS cutting 17 services
- Included: injections for non-specific low back pain, only offered at patient request

Payer Levers

TABLE. Tools to Target Low-Value Care¹²


Provider Facing	Patient Facing
<p>Coverage policies</p> <ul style="list-style-type: none">• Do not reimburse for services that are clearly inappropriate given data from claims and enrollment files.• Ensure medical policies do not require unneeded services in order for patients to receive coverage of medically unnecessary services.	<p>Network design</p> <ul style="list-style-type: none">• Steer patients to providers and plans that minimize the use of inappropriate medical services, including through tools such as shared decision making, which has been shown to reduce unnecessary care.¹⁶
<p>Payment rates and payment models</p> <ul style="list-style-type: none">• Adjust allowed amounts to reduce incentives to provide commonly over-used/potentially harmful services.• Use a composite measure of low-value care in pay-for-performance programs, such as has been suggested for the Medicare Merit-based Incentive Payment System.¹³• Accelerate adoption of new payment models that reduce incentives for overuse, such as ACO programs with downside risk.¹⁴	<p>Utilization management</p> <ul style="list-style-type: none">• Consider narrowly targeted PA programs.¹⁷• Minimize the administrative burden through tools such as electronic PA for a select number of services and with a seamless user-friendly interface.¹⁸
<p>Provider profiling information</p> <ul style="list-style-type: none">• Distribute reports benchmarking the practice patterns of a clinician or practice against those of your peers.¹⁵	<p>Value-based insurance designs</p> <ul style="list-style-type: none">• Align patients' out-of-pocket cost sharing with the value of the underlying service. For example, high-value chronic disease care, such as blood pressure medications, should be free.• For commonly overused services, selectively allow increases in cost sharing to serve as "speed bumps."¹⁹

ACO indicates accountable care organization; PA, prior authorization.

Levers work best in combination

- Multiple and “synergistic” interventions work better in concert than in isolation

For example...



Provider-facing
information, eg CDS

Patient-facing
incentives, eg VBID

Provider-facing
information alone



Low-Value Care Prize Competition

**Accelerating health system transformation from
“how much” to “how well”**

Motivation

The background features several faint, stylized icons: a brain on the left, a glowing lightbulb on the right, and two interlocking gears at the bottom center. A thick, light-colored line forms a large, irregular shape that encompasses the brain and lightbulb, suggesting a process or flow.

- To bring more visibility to initial results of many efforts
- To spark conversations about low-value care and the Top Five
- To accelerate adoption and implementation of novel strategies
- To mobilize diverse thinkers (perhaps even those outside health care) and fresh ideas

Background

- A proposed partnership with Center for Technology and Medical Policy (CMTP)
- Process and concept modeled around Hearst Health Prize or AMGA Acclaim Prize
- Option to focus on Top Five or a broader look at low-value care and or clinical waste
 - Could do multiple categories



Potential timeline

**Now – January
2019**

- Develop project proposal and fill budget
- Recruit panel of judges
- **Establish judging criteria for submissions**

Spring 2019

- Announce the prize
- Publicize
- Open up for submissions


Summer 2019

- Announce finalists
- Judge panel deliberate finalists

Fall 2019

- Conference to showcase finalists
- Announce top prizes (can be multiple “winners”)

Submission process



Working titles

- Low-Value Care Prize
- Health Waste Reduction Prize
- Waste in Health Innovation Prize
- Low-Value Care Task Force Prize
- The Prize for Low-Value Care Reduction
- The Health Care Waste Prize
- Waste Task Force prize

Suggestions welcome!



Reactions and discussion

We look forward to seeing you at the
next LVC-TF meeting in March!

Save the date: March 14, 2019